Company News » Events » TIDES TV Interview: Neoantigen Peptides in Personalized Cancer Immunotherapy
TIDES TV Interview: Neoantigen Peptides in Personalized Cancer Immunotherapy
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen identification and production are major bottlenecks in the development of personalized cancer immunotherapies. In this webinar, we will review how these neoantigen peptides are used during various stages of personalized therapeutic development to increase treatment efficacy. The talk will also discuss GenScript's four tier platform for synthesizing reliable neoantigen peptides for the personalized medicine community.